Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion

By: Hataf Finance

December 26, 2023

Less than 1 min.

Bristol Myers to Acquire RayzeBio in Deal Valued at .1 Billion

Bristol Myers Squibb to acquire therapeutic radiopharmaceuticals company RayzeBio for $62.50 per share in cash.

Continue reading this article with a Barron’s subscription.

Previous article

Tesla Bull Raises Price Target for 2024 as Tesla Enters Next Phase of Growth

Next article

World’s Largest Reserve Of REE Lithium Discovered Beneath California’s Salton Sea: $540 Billion Motherlode Could Meet America’s Supply Demands For Decades

OpenAI buys a remote collaboration platform

Fearing Losses, Banks Are Quietly Dumping Real Estate Loans

Dozens of Tesla Cybertrucks vandalized by someone who really doesn’t like Elon Musk